MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease

V. Fung, J. Aldred, F. Bergquist, E. Danielsen, A. Jeong, J. Jia, A. Spiegel, S. Talapala, C. Carroll (Westmead, Australia)

Meeting: 2023 International Congress

Abstract Number: 54

Keywords: Dopamine agonists, Levodopa(L-dopa), Parkinson’s

Category: Parkinson’s Disease: Clinical Trials

Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study.

Background: LDP/CDP is a soluble formulation of levodopa (LD)/carbidopa prodrugs administered as 24-hour/day continuous subcutaneous infusion (CSCI). In a 52-week, open-label phase 3 study, LDP/CDP demonstrated a favorable risk/benefit profile in patients with aPD (NCT03781167); those who completed the parent trial were eligible to enroll in an OLE (NCT04379050).

Method: Patients in the parent study were aged ≥30 years with inadequately controlled (≥2.5 hours “Off” time/day), LD-responsive, idiopathic aPD. The ongoing OLE consists of a 96-week Primary Treatment Period and optional Extended Treatment Period. LDP/CDP infusions are individually optimized (600–4250 mg LD equivalents/24 hours). The primary endpoint is safety/tolerability. Key secondary endpoints are change from OLE baseline for mean normalized daily “Off” and “On” times and morning akinesia (“Off” upon awakening). Efficacy data are presented through Week 84 (interim data cutoff August 17, 2022).

Results: Overall, 137 patients completed the parent study, 129 (94.2%) enrolled in the OLE; 113 (87.6%) are currently ongoing in the OLE. The most common reason for discontinuation was treatment-emergent adverse events (AE; 8 [6.2%]). At OLE baseline, most patients are male (63.6%), White (86.8%), with a mean (SD) age of 63.1 (9.2) years, time since PD diagnosis of 10.2 (4.9) years, and “Off” time of 2.53 (2.9) hours. The mean person-years of study drug exposure (parent study and OLE) is 314.0 years, with a mean (SD) exposure duration of 470.1 (386.9) days. Overall, 83.7% of patients experienced ≥1 AE; most were non-serious and mild or moderate in severity. “Off” and “On” times were generally stable through Week 84 in the OLE (“On” time without troublesome dyskinesia −0.6 [2.9] hours, P=.252); “On” time with troublesome dyskinesia (−0.2 [1.2] hours, P=.364); “Off” time (+0.9 [2.7] hours, P=.102) [figure]. At Week 84, 75% of patients reported awakening in the “On” state (n/N= 15/20).

Conclusion: Long-term CSCI of LDP/CDP was generally safe and well tolerated and effected sustained improvements in motor fluctuations and morning akinesia that were consistent with the parent study.

Fung Table

Fung Figure

To cite this abstract in AMA style:

V. Fung, J. Aldred, F. Bergquist, E. Danielsen, A. Jeong, J. Jia, A. Spiegel, S. Talapala, C. Carroll. Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/open-label-extension-study-of-long-term-safety-and-tolerability-of-foslevodopa-foscarbidopa-for-treatment-of-advanced-parkinsons-disease/. Accessed June 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/open-label-extension-study-of-long-term-safety-and-tolerability-of-foslevodopa-foscarbidopa-for-treatment-of-advanced-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Welcome to the MDS Abstracts Site
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • Life expectancy with and without Parkinson’s disease in the general population
    • The hardest symptoms that bother patients with Parkinson's disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley